Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma
Cancer,  Clinical Article

Barta SK et al. – The current analysis provided additional level 2 evidence supporting the use of concurrent rituximab plus infusional etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R–EPOCH) in patients with human immunodeficiency virus (HIV)–associated lymphoma and a CD4 count >50/µL, and the results support the design of an ongoing phase 3 trial comparing concurrent R–EPOCH with R–CHOP in immunocompetent patients with diffuse large B–cell lymphoma .

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Oncology Articles

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close